Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
Shimada A, Hanafusa T, Yasui A, Lee G, Taneda Y, Sarashina A, Shiki K, George J, Soleymanlou N, Marquard J. Shimada A, et al. Among authors: yasui a. Diabetes Obes Metab. 2018 Sep;20(9):2190-2199. doi: 10.1111/dom.13351. Epub 2018 Jun 5. Diabetes Obes Metab. 2018. PMID: 29766633 Free PMC article. Clinical Trial.
Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study.
Terauchi Y, Utsunomiya K, Yasui A, Seki T, Cheng G, Shiki K, Lee J. Terauchi Y, et al. Among authors: yasui a. Diabetes Ther. 2019 Jun;10(3):951-963. doi: 10.1007/s13300-019-0604-8. Epub 2019 Mar 25. Diabetes Ther. 2019. PMID: 30912033 Free PMC article.
Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial.
Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova A, Chin R, Hirase T, Shibahara T, Hayashi N, Kansal A, Kaspers S, Okamura T. Kaku K, et al. Among authors: yasui a. Clin Ther. 2019 Oct;41(10):2021-2040.e11. doi: 10.1016/j.clinthera.2019.07.016. Epub 2019 Sep 25. Clin Ther. 2019. PMID: 31561882 Free article. Clinical Trial.
Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Watada H, Yamauchi T, Yamamoto F, Taniguchi A, Yarush L, Heilmann C, Yasui A. Watada H, et al. Among authors: yasui a. Expert Opin Drug Saf. 2020 Sep;19(9):1193-1202. doi: 10.1080/14740338.2020.1782884. Epub 2020 Jul 2. Expert Opin Drug Saf. 2020. PMID: 32552153
Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
Seino Y, Kim DJ, Yabe D, Tan EC, Chung WJ, Ha KH, Nangaku M, Node K, Klement R, Yasui A, Lei WY, Lee S, Kyaw MH, Deruaz-Luyet A, Brodovicz KG, H-H Sheu W; EMPRISE East Asia study group. Seino Y, et al. Among authors: yasui a. Endocrinol Diabetes Metab. 2020 Sep 16;4(1):e00183. doi: 10.1002/edm2.183. eCollection 2021 Jan. Endocrinol Diabetes Metab. 2020. PMID: 33532619 Free PMC article.
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D, Shiki K, Suzaki K, Meinicke T, Kotobuki Y, Nishida K, Clark D, Yasui A, Seino Y. Yabe D, et al. Among authors: yasui a. BMJ Open. 2021 Apr 7;11(4):e045844. doi: 10.1136/bmjopen-2020-045844. BMJ Open. 2021. PMID: 33827843 Free PMC article. Clinical Trial.
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
Sheu WH, Seino Y, Tan EC, Yabe D, Ha KH, Nangaku M, Chung WJ, Node K, Yasui A, Lei WY, Lee S, Ustyugova A, Klement R, Deruaz-Luyet A, Kyaw MH, Kim DJ; EMPRISE East Asia study group. Sheu WH, et al. Among authors: yasui a. J Diabetes Investig. 2022 May;13(5):810-821. doi: 10.1111/jdi.13728. Epub 2022 Jan 11. J Diabetes Investig. 2022. PMID: 34859609 Free PMC article.
393 results